Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)

Next Previous
Trial Profile

Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Heparin
  • Indications Thrombosis
  • Focus Adverse reactions; Registrational
  • Acronyms BRAVO 2/3; BRAVO-3
  • Sponsors The Medicines Company

    • Most Recent Events

    • 04 Apr 2022 Results assessing the effect of CAD on clinical outcomes following TAVR and the interaction between CAD and different periprocedural anticoagulant, presented at the 71st Annual Scientific Session of the American College of Cardiology.
    • 04 Apr 2022 Results assessing the effect of Chronic Thrombocytopenia on clinical outcomes presented at the 71st Annual Scientific Session of the American College of Cardiology
    • 15 Nov 2021 Results of subgroup analysis assessing Impact of anemia on short-term outcomes after Impact of anemia on short-term outcomes after transcatheter aortic valve replacement (TAVR) published in the Catheterization and Cardiovascular Interventions
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top